The clinical-stage biopharmaceutical company priced its IPO at $18 per share and opened at $21. Latigo focuses on non-opioid pain medicines, and its lead asset LTG-001 for acute pain demonstrated 50% greater pain relief than hydrocodone in a 343-patient trial, positioning it for a potential opioid-free label claim. Phase 3 trials for LTG-001 are set to launch in the second half of 2026, with results expected in the second half of 2027.